Follistatin + B-Complex (SlimAssist Blend)
/ Two-component blend — recombinant follistatin (FST-315 or FST-344, vendor-dependent) plus B-vitamin complex (composition varies)ALIAS · SlimAssist (FLGR/B-Complex) · Follistatin/B-vitamin blend
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Vendor-marketed blend combining a follistatin protein component with B-vitamin complex; presented commercially as a body-composition adjunct. Neither the specific follistatin source nor the B-vitamin formulation is consistently disclosed across sellers; the blend has no published clinical trial.
Pharmacological rationale combines myostatin/activin sequestration via follistatin (see follistatin component pages) with general metabolic-cofactor support via B vitamins. The B-vitamin component does not have specific peptide-class pharmacology; it is a nutritional adjunct.
None for the blend. Follistatin component evidence is preclinical (or AAV-gene-therapy clinical for the FST-344 isoform). B-vitamin complex efficacy as a body-composition aid is not supported by separate peptide-research literature.
No combined safety database. The injectable B-vitamin component has known adverse events on its own (anaphylactoid reactions to thiamine, niacin flushing) that compound the unknown follistatin-injection risk.
Regulatory status
- FDA status:
- Not FDA-approved
The blend exists primarily as a marketing construct rather than a pharmacological design. Vendors do not consistently disclose the follistatin isoform or the B-vitamin formulation; product-to-product comparability is not assured.